Decoy Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 21, 2025
DCOY$1.11+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Twelve Months Ended December 31 | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(5,575,777) | $(12,542,693) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation, amortization and impairment | 4,424 | 10,051 |
| Equity-based compensation expense | 273,730 | 524,838 |
| Grant receivable writeoff | — | 130,000 |
| Changes in operating assets and liabilities: | ||
| Grants receivable | — | 1,480,490 |
| Prepaid expenses and other current assets | 492,471 | 807,770 |
| Accounts payable | 334,141 | (2,255,477) |
| Accrued expenses and other current liabilities | (54,326) | (1,001,116) |
| Net cash (used in) operating activities | (4,525,337) | (12,846,137) |
| Financing activities | ||
| Proceeds from issuance of equity securities | 1,526,460 | 6,920,529 |
| Payments on note payable | (466,505) | (280,917) |
| Net cash provided by financing activities | 1,059,955 | 6,639,612 |
| Net decrease in cash, cash equivalents and restricted cash | (3,465,382) | (6,206,525) |
| Cash, cash equivalents and restricted cash at beginning of period | 5,899,910 | 12,106,435 |
| Cash, cash equivalents and restricted cash at end of period | $2,434,528 | $5,899,910 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $10,643 | $14,754 |
| Non-cash investing and financing activities: | ||
| Insurance premium financed by note payable | $398,728 | $570,560 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.